Serological evaluation of patients who present with a subacute neurological disorder of undetermined etiology, especially those with known risk factors for cancer
Directing a focused search for cancer
Investigating neurological symptoms that appear in the course of, or after, cancer therapy, and are not explainable by metastasis
Differentiating autoimmune neuropathies from neurotoxic effects of chemotherapy
Monitoring the immune response of seropositive patients in the course of cancer therapy
Detecting early evidence of cancer recurrence in previously seropositive patients
If IFA (ANN1S, ANN2S, ANN3S, PCABP, PCAB2, PCATR, AMPHS, CRMS, AGN1S) patterns are indeterminate, paraneoplastic autoantibody Western blot is performed at an additional charge.
If IFA patterns suggest CRMP-5-IgG, CRMP-5-IgG Western blot is performed at an additional charge.
If IFA pattern suggest NMO/AQP4-IgG, NMO/AQP4-IgG FACS is performed at an additional charge.
If NMO/AQP4-IgG FACS screen assay requires further evaluation, then NMO/AQP4-IgG FACS titration assay is performed at an additional charge.
If IFA patterns suggest amphiphysin antibody, amphiphysin Western blot is performed at an additional charge.
If IFA patterns suggest GAD65 antibody, GAD65 antibody radioimmunoassay is performed at an additional charge.
If IFA pattern suggest NMDA-R, NMDA-R Ab CBA and/or NMDA-R Ab IF Titer Assay is performed at an additional charge.
If IFA pattern suggest AMPA-R, AMPA-R Ab CBA and/or AMPA-R Ab IF Titer Assay is performed at an additional charge.
If IFA pattern suggest GABA-B-R, GABA-B-R Ab CBA and/or GABA-B-R Ab IF Titer Assay is performed at an additional charge.
If ACh receptor binding antibody is >0.02, ACh receptor modulating antibodies and CRMP-5-IgG Western blot are performed at an additional charge.
CRMP-5-IgG Western blot is also performed by specific request for more sensitive detection of CRMP-5-IgG. Testing should be requested in cases of subacute basal ganglionic disorders (chorea, Parkinsonism), cranial neuropathies (especially loss of vision, taste, or smell) and myelopathies.
If VGKC >0.00, LGI1-IgG CBA, S and CASPR2-IgG CBA, S are performed at an additional charge.
The following algorithms are available in Special Instructions
-Paraneoplastic Evaluation Algorithm
-Hereditary Peripheral Neuropathy Diagnostic Algorithm
ANN1S, ANN2S, ANN3S, PCABP, PCAB2, PCATR, AMPHS, CRMS, AGN1S, AMPIS, NMDIS, GABIS: Indirect Immunofluorescence Assay (IFA)
STR: Enzyme Immunoassay (EIA)
CCPQ, CCN, ARBI, ARMO, GANG, VGKC: Radioimmunoassay (RIA)
WBN, ABLOT: Western Blot
NMDCS, AMPCS, GABCS, LG1CS, CS2CS: Cell-Binding Assay (CBA)
NMOTS: Flow Cytometry
